Publications by authors named "G Cozon"
Purpose: Subcutaneous immunoglobulin replacement therapy (IgRT) may be administered once a week with a pump or every other day with a syringe (rapid push). The objective of the study was to compare the impact of pump and rapid push infusions on patient's life quality index (LQI).
Methods: This study was a randomized, crossover, multicenter, non-inferiority trial conducted in adults with primary immunodeficiency (PID) accustomed to weekly infusions at home by pump.
Article Synopsis
- - Patients with primary immunodeficiency (PID) often receive immunoglobulin replacement therapy (IgRT) via methods like subcutaneous infusions using either an automated pump (P) or manual syringe push (RP), with P being less frequent but longer in duration compared to the more frequent but quicker RP infusions.
- - A study involving interviews with PID patients revealed that while RP is slightly more cost-effective and has similar efficacy to P, many patients preferred P due to better integration into their daily routine and less frequent reminders of their disease.
- - The focus group indicated that the complexity of living with PID influences their delivery method preference, as patients found RP cumbersome and not necessarily time-saving, suggesting that healthcare providers should explore these personal experiences further
A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
Patient Prefer Adherence
July 2017
Objective: To assess quality of life and satisfaction regarding immunoglobulin-replacement therapy (IgRT) treatment according to the route (intravenous Ig [IVIg] or subcutaneous Ig [SCIg]) and place of administration (home-based IgRT or hospital-based IgRT).
Subjects And Methods: Children 5-15 years old treated for primary immunodeficiency disease (PIDD) with IgRT for ≥3 months were included in a prospective, noninterventional cohort study and followed over 12 months. Quality of life was assessed with the Child Health Questionnaire - parent form (CHQ-PF)-50 questionnaire.
Background: Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicenter study of patients with primary and secondary immunodeficiencies in France, treatment modalities (primary endpoint), efficacy, safety, tolerability, quality of life, and treatment satisfaction were evaluated using descriptive statistics.
Results: Starting in January 2012, 117 patients were enrolled (99 adults, 18 children).
Background: IgG replacement therapy (IgRT) in primary immunodeficiencies (PID) is a lifelong treatment which may be administered intravenously (IVIg) or subcutaneously (SCIg), at hospital or at home. The objective of the VISAGE study was to investigate if route and/or place for IgRT impact patients' satisfaction regarding IgRT and quality of life (QoL) in real-life conditions.
Methods: The study enrolled PID patients at least 15 years old receiving IgRT for at least 3 months.